ArticleArchives of Razi Institute2025
Immunogenic Potential of Chitosan Nanoparticles Encapsulating Recombinant SlyB Antigen of Enterotoxigenic Escherichia coli (ETEC) in an Animal Model.
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal bacterial infections are a significant cause of mortality in developing countries, with Enterotoxigenic Escherichia coli (ETEC) being a leading cause of severe diarrheal diseases. These infections are characterized by the production of enterotoxins and colonization factors that disrupt the small intestine, leading to diarrhea. While antibiotic treatments face limitations, vaccination has emerged as a critical tool for prevention. This study evaluates the immunogenicity of chitosan nanoparticles (NPs) that encapsulates the recombinant surface antigen SlyB of ETEC in an animal model. The SlyB antigen was expressed in an expression vector, purified, and encapsulated into chitosan nanoparticles using the ionic gelation method. Rabbits were immunized using three different administration methods: oral, oral-injection, and injection. Antibody levels in serum and feces were measured via ELISA, and the neutralization ability of immune sera was assessed using an ileal loop assay. The study's findings revealed that the oral administration of chitosan nanoparticles led to the highest titers of serum IgG and fecal IgA antibodies, suggesting a potential for enhanced mucosal immune responses.The encapsulation of the recombinant SlyB protein within the chitosan nanoparticles not only maintained antigen stability but also promoted controlled release, thereby stimulating robust cellular and humoral immunity.The efficacy of immune sera in neutralizing ETEC toxins was confirmed through a challenge test, with the oral vaccination group demonstrating the most significant neutralizing activity. This study underscores the potential of chitosan nanoparticles as an effective delivery platform for mucosal vaccines against ETEC.By encapsulating recombinant antigens, this method not only enhances immunogenicity but also offers a promising alternative to conventional vaccination strategies for diarrheal diseases.Further research is recommended to explore scalability and efficacy in broader populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.